# Moksha8

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/moksha8

- Industry: Pharmaceuticals
- Headquarters: Sao Paulo, Brazil
- Website: www.moksha8.com
- Total disclosed funding: $125M
- Latest round: Series C (Oct 4, 2010)
- Investors on record: 5

## About

Moksha8 specializes in developing and commercializing innovative pharmaceuticals through strategic partnerships, particularly addressing critical healthcare needs in Latin America.Founded in 2007 and headquartered in Sao Paulo, Brazil, Moksha8 focuses on forming collaborations with leading pharmaceutical companies. The CEO, Joel Barlan, leads the company that has not undergone significant changes in its operational strategy. Moksha8 has successfully completed 8 deals, with its most recent being a Trade Sale to Forest Laboratories, Inc. on October 22, 2012, for USD 47.00 mn, raising a total of USD 47.00 mn so far.Moksha8 Pharmaceuticals specializes in forming strategic partnerships with leading pharmaceutical companies to develop and commercialize innovative medicines across various therapeutic areas, including central nervous system disorders, cardiometabolism, respiratory issues, gastroenterology, oncology and hematology, and rare diseases. Their product portfolio includes advanced therapies designed to address significant medical needs, particularly in Latin America. Notable products include Voraxaze® (Glucarpidase), utilized for treating cancer patients, and Qelbree® (Viloxazine XR), which addresses attention-deficit/hyperactivity disorder. Moksha8 targets a diverse client base comprising healthcare providers, hospitals, and specialty pharmacies, ensuring that patients receive essential treatments in markets such as Brazil, Mexico, and other Latin American countries.Moksha8 Pharmaceuticals generates revenue through strategic licensing agreements and exclusive partnerships with established pharmaceutical firms, facilitating the entry of innovative treatments into the Latin American market. Transactions typically occur through B2B arrangements, where Moksha8 collaborates with its partners to bring products from regulatory approval to full commercialization. The structure of these transactions often involves upfront licensing fees, milestone payments, and royalties on product sales. While specific pricing plans for flagship products such as Voraxaze® and Qelbree® were not disclosed, the company's revenue model is designed to capitalize on the growing demand for effective therapies in their targeted regions, enabling them to solidify relationships with their partners and expand their market presence.Looking forward, Moksha8 plans to leverage its recent funding from the Trade Sale to Forest Laboratories, Inc. to support the development of upcoming innovative products and expand its market reach. The company is set to launch new therapies across its therapeutic areas while targeting additional markets in Latin America. Specifically, Moksha8 intends to enhance its presence in Brazil and Mexico by 2015, capitalizing on the recent funding commitment of USD 125 mn over the next two years to facilitate these growth initiatives.

## Funding rounds

- Series C, Oct 4, 2010, $61M — Montreux Equity Partners, TPG Biotech, Watson Pharmaceuticals Inc.
- Series C, Dec 1, 2009, $25M — Montreux Equity Partners, TPG Biotech
- Series A, Jan 31, 2008, $24M — TPG Biotech
- Series B, Jan 31, 2008, $15M — TPG Biotech, Votorantim Group, Lit Tele LLC

## Investors

- TPG Biotech (https://capitalatlas.ai/funds/tpg-biotech) — Series A, Series B, Series C
- Votorantim Group — Series B
- Lit Tele LLC — Series B
- Montreux Equity Partners (https://capitalatlas.ai/funds/montreux-equity-partners) — Series C
- Watson Pharmaceuticals Inc. — Series C